Glutamine contains an α-amino group which is in the protonated −NH3+ form under biological conditions and a carboxylic acid group which is in the deprotonated −COO− form, known as carboxylate, under physiological conditions. Research
Glutamine mouthwash may be useful to prevent oral mucositis in people undergoing chemotherapy but intravenous glutamine does not appear useful to prevent mucositis in the GI tract.Glutamine supplementation was thought to have potential to reduce complications in people who are critically ill or who have had abdominal surgery but this was based on poor quality clinical trials. Supplementation does not appear to be useful in adults or children with Crohns disease or inflammatory bowel disease, but clinical studies as of 2016 were underpowered. Supplementation does not appear to have an effect in infants with significant problems of the stomach or intestines.Some athletes use L-glutamine as supplement. Studies support the positive effects of the chronic oral administration of the supplement on the injury and inflammation induced by intense aerobic and exhaustive exercise, but the effects on muscle recovery from weight training are unclear. See also
Isoglutamine

References
External links
Glutamine spectra acquired through mass spectroscopy
"Glutamine". Drug Information Portal. U.S. National Library of Medicine.
Further brain tumor trials are planned in which vorinostat will be combined with other drugs. Including vorinostat in treatment of advanced non-small-cell lung carcinoma (NSCLC) showed improved response rates and increased median progression free survival and overall survival.It has given encouraging results in a phase II trial for myelodysplastic syndromes in combination with idarubicin and cytarabine. Preclinical investigations
Vorinostat is being investigated as a potential HIV latency reversing agent (LRA) as part of an investigational therapeutic strategy known as "shock and kill." Vorinostat was shown to reactivate HIV in latently HIV-infected T cells, both in vitro and in vivo.Vorinostat also has shown some activity against the pathophysiological changes in α1-antitrypsin deficiency and cystic fibrosis. Recent evidence also suggests vorinostat can be a therapeutic tool for Niemann-Pick type C1 (NPC1), a rare lysosomal lipid storage disease.Preclinical experiments by University of Alabama at Birmingham researchers suggest the cancer drugs vorinostat, belinostat and panobinostat might be repurposed to treat infections caused by human papillomavirus, or HPV. See also
Trichostatin A

References
External links
Vorinostat bound to proteins in the PDB